BRPI1006113A2 - "derivado de piridina". - Google Patents

"derivado de piridina".

Info

Publication number
BRPI1006113A2
BRPI1006113A2 BRPI1006113A BRPI1006113A BRPI1006113A2 BR PI1006113 A2 BRPI1006113 A2 BR PI1006113A2 BR PI1006113 A BRPI1006113 A BR PI1006113A BR PI1006113 A BRPI1006113 A BR PI1006113A BR PI1006113 A2 BRPI1006113 A2 BR PI1006113A2
Authority
BR
Brazil
Prior art keywords
pyridine derivative
pyridine
derivative
Prior art date
Application number
BRPI1006113A
Other languages
English (en)
Inventor
Kunihiko Fujii
Makoto Mori
Tomoharu Tsukada
Tsuyoshi Shinozuka
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI1006113A2 publication Critical patent/BRPI1006113A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
BRPI1006113A 2009-03-05 2010-03-03 "derivado de piridina". BRPI1006113A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009051820 2009-03-05
PCT/JP2010/053384 WO2010101164A1 (ja) 2009-03-05 2010-03-03 ピリジン誘導体

Publications (1)

Publication Number Publication Date
BRPI1006113A2 true BRPI1006113A2 (pt) 2016-02-16

Family

ID=42709719

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006113A BRPI1006113A2 (pt) 2009-03-05 2010-03-03 "derivado de piridina".

Country Status (17)

Country Link
US (2) US20120029026A1 (pt)
EP (1) EP2404918B1 (pt)
JP (1) JPWO2010101164A1 (pt)
KR (1) KR20110123253A (pt)
CN (1) CN102341386A (pt)
AU (1) AU2010219705A1 (pt)
BR (1) BRPI1006113A2 (pt)
CA (1) CA2754446A1 (pt)
CO (1) CO6362003A2 (pt)
ES (1) ES2617191T3 (pt)
IL (1) IL214961A0 (pt)
MX (1) MX2011009244A (pt)
RU (1) RU2480463C1 (pt)
SG (1) SG172469A1 (pt)
TW (1) TW201035074A (pt)
WO (1) WO2010101164A1 (pt)
ZA (1) ZA201105479B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
CA2754446A1 (en) 2009-03-05 2010-09-10 Daiichi Sankyo Company, Limited Pyridine derivative
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
TW201219353A (en) * 2010-09-07 2012-05-16 Daiichi Sankyo Co Ltd Manufacturing method of benzoates
EP3321378B1 (en) 2012-02-27 2021-11-10 Becton, Dickinson and Company Compositions for molecular counting
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105705659B (zh) 2013-08-28 2019-11-29 贝克顿迪金森公司 大规模平行单细胞分析
CN105745528A (zh) 2013-10-07 2016-07-06 赛卢拉研究公司 用于以数字方式对阵列上的特征进行计数的方法和系统
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
US10359415B2 (en) * 2014-05-02 2019-07-23 Rosemount Inc. Single-use bioreactor sensor architecture
WO2016131025A1 (en) * 2015-02-13 2016-08-18 Ideation Systems Llc Modular system including multiple detachable sensors
EP3259371B1 (en) 2015-02-19 2020-09-02 Becton, Dickinson and Company High-throughput single-cell analysis combining proteomic and genomic information
WO2016138496A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
CN107406888A (zh) 2015-03-30 2017-11-28 赛卢拉研究公司 用于组合条形编码的方法和组合物
EP3286326B1 (en) 2015-04-23 2025-01-22 Becton, Dickinson and Company Method for whole transcriptome amplification
US11124823B2 (en) 2015-06-01 2021-09-21 Becton, Dickinson And Company Methods for RNA quantification
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
WO2017044574A1 (en) 2015-09-11 2017-03-16 Cellular Research, Inc. Methods and compositions for nucleic acid library normalization
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
EP3452614B1 (en) 2016-05-02 2023-06-28 Becton, Dickinson and Company Accurate molecular barcoding
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
WO2017205691A1 (en) 2016-05-26 2017-11-30 Cellular Research, Inc. Molecular label counting adjustment methods
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
IL265478B2 (en) 2016-09-26 2024-10-01 Becton Dickinson Co Measurement of protein expression using reagents with barcoded oligonucleotide sequences
AU2017359048B2 (en) 2016-11-08 2022-07-21 Becton, Dickinson And Company Methods for expression profile classification
CN109906274B (zh) 2016-11-08 2023-08-25 贝克顿迪金森公司 用于细胞标记分类的方法
WO2018132610A1 (en) 2017-01-13 2018-07-19 Cellular Research, Inc. Hydrophilic coating of fluidic channels
US11319583B2 (en) 2017-02-01 2022-05-03 Becton, Dickinson And Company Selective amplification using blocking oligonucleotides
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP7536450B2 (ja) 2017-06-05 2024-08-20 ベクトン・ディキンソン・アンド・カンパニー 単一細胞用のサンプルインデックス付加
CN111492068B (zh) 2017-12-19 2025-03-21 贝克顿迪金森公司 与寡核苷酸相关联的颗粒
CA3097976A1 (en) 2018-05-03 2019-11-07 Becton, Dickinson And Company High throughput multiomics sample analysis
EP3788170B1 (en) 2018-05-03 2025-01-01 Becton, Dickinson and Company Molecular barcoding on opposite transcript ends
EP3861134B1 (en) 2018-10-01 2024-09-04 Becton, Dickinson and Company Determining 5' transcript sequences
EP3877520B1 (en) 2018-11-08 2025-03-19 Becton, Dickson And Company Whole transcriptome analysis of single cells using random priming
CN109456259A (zh) * 2018-11-27 2019-03-12 武汉珈瑜科技有限公司 酰胺类衍生物及其应用
CN109293566A (zh) * 2018-11-27 2019-02-01 武汉珈瑜科技有限公司 酰胺类衍生物及其应用
EP3894552B1 (en) 2018-12-13 2026-01-28 Becton, Dickinson and Company Selective extension in single cell whole transcriptome analysis
WO2020150356A1 (en) 2019-01-16 2020-07-23 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
EP3914728B1 (en) 2019-01-23 2023-04-05 Becton, Dickinson and Company Oligonucleotides associated with antibodies
CN113454234B (zh) 2019-02-14 2025-03-18 贝克顿迪金森公司 杂合体靶向和全转录物组扩增
US11965208B2 (en) 2019-04-19 2024-04-23 Becton, Dickinson And Company Methods of associating phenotypical data and single cell sequencing data
WO2021016239A1 (en) 2019-07-22 2021-01-28 Becton, Dickinson And Company Single cell chromatin immunoprecipitation sequencing assay
EP4055160B1 (en) 2019-11-08 2024-04-10 Becton Dickinson and Company Using random priming to obtain full-length v(d)j information for immune repertoire sequencing
CN115279919A (zh) 2020-01-13 2022-11-01 贝克顿迪金森公司 使用含有du的寡核苷酸的细胞捕获
CN115244184A (zh) 2020-01-13 2022-10-25 贝克顿迪金森公司 用于定量蛋白和rna的方法和组合物
WO2021155057A1 (en) 2020-01-29 2021-08-05 Becton, Dickinson And Company Barcoded wells for spatial mapping of single cells through sequencing
US12153043B2 (en) 2020-02-25 2024-11-26 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
WO2021231779A1 (en) 2020-05-14 2021-11-18 Becton, Dickinson And Company Primers for immune repertoire profiling
CN115803445A (zh) 2020-06-02 2023-03-14 贝克顿迪金森公司 用于5撇基因表达测定的寡核苷酸和珠
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
WO2022026909A1 (en) 2020-07-31 2022-02-03 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
MX2023005371A (es) 2020-11-09 2023-05-22 Eisai R&D Man Co Ltd Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.
WO2022109343A1 (en) 2020-11-20 2022-05-27 Becton, Dickinson And Company Profiling of highly expressed and lowly expressed proteins
CN116685850A (zh) 2020-12-15 2023-09-01 贝克顿迪金森公司 单细胞分泌组分析

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
IE910278A1 (en) * 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
FR2751649B1 (fr) 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US5968960A (en) 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
PL351898A1 (en) 1999-04-06 2003-06-30 Sankyo Co O-substituted derivatives of carboxylic acids
JP4169450B2 (ja) 1999-04-07 2008-10-22 第一三共株式会社 インスリン抵抗性改善剤
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
DE60106148T2 (de) 2000-07-13 2006-02-23 Sumitomo Chemical Co. Ltd. Verfahren zur Herstellung von N-Acylnitroanilinderivaten
JP2002193948A (ja) 2000-10-06 2002-07-10 Sankyo Co Ltd α−置換カルボン酸誘導体を含有する糖尿病治療剤
ES2292937T3 (es) 2002-02-21 2008-03-16 Eli Lilly And Company Moduladores para el receptor activado por el proliferador de peroxisomas.
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2004013109A1 (ja) 2002-08-02 2004-02-12 Sankyo Company, Limited レゾルシノール誘導体
JP2004067629A (ja) * 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP2004315404A (ja) 2003-04-15 2004-11-11 Sankyo Co Ltd ベンゾイミダゾール誘導体を含有する医薬
WO2005037763A1 (en) 2003-10-14 2005-04-28 Eli Lilly And Company Phenoxyether derivatives as ppar modulators
WO2005042497A2 (en) 2003-10-28 2005-05-12 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
CN101068770B (zh) 2004-09-28 2012-01-04 三共株式会社 制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
MX2009010790A (es) * 2007-04-05 2009-10-29 Daiichi Sankyo Co Ltd Derivados de heteroarilo biciclico fusionados.
CA2754446A1 (en) 2009-03-05 2010-09-10 Daiichi Sankyo Company, Limited Pyridine derivative

Also Published As

Publication number Publication date
RU2480463C1 (ru) 2013-04-27
ZA201105479B (en) 2012-04-25
IL214961A0 (en) 2011-11-30
JPWO2010101164A1 (ja) 2012-09-10
MX2011009244A (es) 2011-09-26
CN102341386A (zh) 2012-02-01
AU2010219705A1 (en) 2011-07-21
EP2404918A1 (en) 2012-01-11
US20130045994A1 (en) 2013-02-21
KR20110123253A (ko) 2011-11-14
US20120029026A1 (en) 2012-02-02
RU2011136681A (ru) 2013-03-10
CO6362003A2 (es) 2012-01-20
SG172469A1 (en) 2011-08-29
TW201035074A (en) 2010-10-01
ES2617191T3 (es) 2017-06-15
CA2754446A1 (en) 2010-09-10
EP2404918A4 (en) 2012-08-01
WO2010101164A1 (ja) 2010-09-10
EP2404918B1 (en) 2016-11-30
US8946264B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
FR24C1047I2 (fr) Derive de 4-pyrimidinesulfamide
BRPI0810202A2 (pt) Derivados de piridina
EP2404918A4 (en) pyridine
BRPI1011414A8 (pt) "método."
EP2226315A4 (en) 2-aminoquinazoline DERIVATIVE
EP2213673A4 (en) Pyridone-substituted dihydropyrazolopyrimidine derivative
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BR112012000763A2 (pt) derivados de piridin-4-ila
BR112012012872A2 (pt) "pirrolindinas de espiroindolinona"
EP2376493A4 (en) DIHYDROPYRIMIDOPYRIMIDINDERIVAT
EP2380877A4 (en) PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
UY33125A (es) Diaza-espiro-[5,5]-undecanos
ATE502012T1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivat
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
EP2336132A4 (en) MORPHOLINPURINDERIVAT
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI1008173A2 (pt) "derivados de piridina espiroindolinona"
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0906357A2 (pt) Derivados de oxazepinopirimidona arilamida substituídos
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
EP2459573A4 (en) SUBSTITUTED 1,2-AZABORIN HETEROCYCLES
BRPI1016192A2 (pt) derivados de soxazol.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2377 DE 26-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.